U.S., June 27 -- ClinicalTrials.gov registry received information related to the study (NCT07670546) titled 'A Phase III Study of the Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica' on June 19.
Brief Summary: The primary objective of the study is to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously every 2 weeks compared with placebo in participants with polymyalgia rheumatica (PMR). The secondary objectives are to evaluate the steroid-sparing effect, inflammatory markers, safety, tolerability, immunogenicity, and pharmacokinetics of OKZ in participants with PMR compared with placebo. The exploratory objectives are to evaluate OKZ efficacy in selected participant subgroups, biomarkers of...